Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You and Your Team.

Learn More →

Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated With Bone-Targeting Radioisotopes

Overall Survival in Men With Bone Metastases From Castration-Resistant Prostate Cancer Treated... Key PointsQuestionWhat is the benefit of bone-targeted radioisotope (RI) use in metastatic castration-resistant prostate cancer, and is there any difference between α-emitting and β-emitting RIs? FindingThis meta-analysis of individual patient data was based on 6 randomized clinical trials including 2081 patients that compared RI use with no RI use study arms with no overall significant difference. While an α-emitting RI (radium 223) was significantly associated with higher overall survival and higher symptomatic skeletal event–free survival, a β-emitting RI (strontium-89) was not associated with these outcomes. MeaningThis meta-analysis suggests a benefit of α-emitting RIs but not of β-emitting RIs for overall survival and symptomatic skeletal event–free survival, although caution is necessary for generalizability of these results, given the between-trial heterogeneity. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA Oncology American Medical Association

Loading next page...
 
/lp/american-medical-association/overall-survival-in-men-with-bone-metastases-from-castration-resistant-XfDdsqLPcU
Publisher
American Medical Association
Copyright
Copyright 2019 American Medical Association. All Rights Reserved.
ISSN
2374-2437
eISSN
2374-2445
DOI
10.1001/jamaoncol.2019.4097
Publisher site
See Article on Publisher Site

Abstract

Key PointsQuestionWhat is the benefit of bone-targeted radioisotope (RI) use in metastatic castration-resistant prostate cancer, and is there any difference between α-emitting and β-emitting RIs? FindingThis meta-analysis of individual patient data was based on 6 randomized clinical trials including 2081 patients that compared RI use with no RI use study arms with no overall significant difference. While an α-emitting RI (radium 223) was significantly associated with higher overall survival and higher symptomatic skeletal event–free survival, a β-emitting RI (strontium-89) was not associated with these outcomes. MeaningThis meta-analysis suggests a benefit of α-emitting RIs but not of β-emitting RIs for overall survival and symptomatic skeletal event–free survival, although caution is necessary for generalizability of these results, given the between-trial heterogeneity.

Journal

JAMA OncologyAmerican Medical Association

Published: Feb 12, 2020

References